View : 104 Download: 0

Outcome of Multiple Myeloma Patients With Hepatitis B Surface Antigen: Korean Multiple Myeloma Working Party 2103 Study

Title
Outcome of Multiple Myeloma Patients With Hepatitis B Surface Antigen: Korean Multiple Myeloma Working Party 2103 Study
Authors
YiJun HoLeeJung LimYoo JinKangHye JinParkYoung HoonYuhYoung JinLimSung-NamKimHyo JungJungSung-HoonJe-JungChoHee JeongMoonJoon HoYhimHo-YoungKihyun
Ewha Authors
박영훈
SCOPUS Author ID
박영훈scopus
Issue Date
2024
Journal Title
Clinical Lymphoma, Myeloma and Leukemia
ISSN
2152-2650JCR Link
Citation
Clinical Lymphoma, Myeloma and Leukemia vol. 24, no. 2, pp. e50 - e57.e2
Keywords
Hepatitis B virusImmune suppressionMultiple myelomaProphylaxisReactivation
Publisher
Elsevier Inc.
Indexed
SCOPUS WOS scopus
Document Type
Article
Abstract
Background: Hepatitis B virus reactivation (HBVr) is a well-known complication of systemic chemotherapy for particularly hematologic malignancies in HBV carriers. We performed a multicenter retrospective study to investigate the incidence and risk factors of HBVr in patients with hepatitis B surface antigen (HBsAg)-positive multiple myeloma (MM). Methods: We included 123 patients with HBsAg-positive MM who had received systemic therapy. The primary objective of the study was to evaluate the incidence of HBVr in patients with HBsAg-positive MM. Results: The median age was 59 years, and 72 patients were male. With a median follow-up duration of 41.4 months, there were 43 instances of HBVr in 35 patients (28.5%): 29 treatment-related HBVr occurred during 424 treatments. Treatments containing antiviral prophylaxis were associated with a significantly lower incidence of HBVr compared to those without (14.4% vs. 1.9%, P < 0.001). Moreover, treatment with cyclophosphamide (P = 0.002) and doxorubicin (P = 0.053) were risk factors for HBVr; stem cell transplantation was not associated with HBVr. There was no significant difference in overall survival between patients with and without HBVr (P = 0.753) and myeloma progression was the major cause of death. Conclusion: Considering the low incidence of HBVr in patients who had received antiviral prophylaxis, HBsAg-positivity should not impede patients from receiving optimal antimyeloma treatment or participating in clinical trials. © 2023
DOI
10.1016/j.clml.2023.10.004
Appears in Collections:
의료원 > 의료원 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE